A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Items 201–300 of 535
Fusion of core pathways reveals a horizontal synergistic mechanism underlying combination therapy
Wang, Z., Jing, Z., Zhou, C., Zhang, L., Cheng, J., Zhang, Z., Liu, J. H., Xu, C., Li, P.-T., & Wang, Y.-Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.05.046 · Cited by 28
Li, Q., Li, X., Li, C., Chen, L., Song, J., Tang, Y., & Xu, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0014774 · Cited by 27
Bibliometric Analysis of Network Pharmacology in Traditional Chinese Medicine
Miao, R.-P., Meng, Q., Wang, C., & Yuan, W. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1583773 · Cited by 27
“In terms of methodological innovation, Kitano, 2007 [44], noted that there were limitations in analyzing the efficacy of drugs for the treatment of diseases solely from the aspects of drug targets andmechanisms of action.”
BackgroundNovel Pathogenic Insights in the Primary Prevention of Cardiovascular Disease
Napoli, C., & Cacciatore, F. (2009) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2009.01.003 · Cited by 27
“By reformulating communication theories that are well established in engineering, it is possible to more effectively control the robustness of living systems, particularly at the cellular level.(172) These can be used to identify novel drug targets to determine the appropriate dosing of a drug, based on metabolomic pr…”
BackgroundChemical probes for biological systems
García-Serna, R., & Mestres, J. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.11.004 · Cited by 26
Yang, J., Ran, Y., Liu, S., Ren, C., Lou, Y., Ju, P., Li, G., Li, X., & Zhang, D. (2023) · Advanced Science · doi:10.1002/advs.202307173 · Cited by 26
Is there a case for selectively promiscuous anticancer drugs?
Fernández, A., Crespo, A., & Tiwari, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.10.008 · Cited by 26
Klein, A., Wrulich, O. A., Jenny, M., Gruber, P., Becker, K., Fuchs, D., Gostner, J. M., & Überall, F. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-133 · Cited by 28
“The strong interconnection of network 7 with other subnetworks might indicate that the represented interactions are involved in the regulation of some important cell behavior, as the removal of this part would affect the whole interaction network [38].”
BackgroundShoemaker, J. E., Gayen, K., García‐Reyero, N., Perkins, E. J., Villeneuve, D. L., Liu, L., & Doyle, F. J. (2010) · BMC Systems Biology · doi:10.1186/1752-0509-4-89 · Cited by 26
“Aspects of biological networks, such as robustness, can be exploited to guide network elucidation [6,7] and reveal pathways critical to the body’s response to toxin exposure.”
BackgroundSynecological farming: Theoretical foundation on biodiversity responses of plant communities
Funabashi, M. (2016) · Plant Biotechnology · doi:10.5511/plantbiotechnology.16.0219a · Cited by 26
Goltsov, A., Faratian, D., Langdon, S. P., Bown, J., Goryanin, I., & Harrison, D. J. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.011 · Cited by 26
Szalay, K. Z., & Csermely, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078059 · Cited by 26
“Sequential perturbations have been suggested as a key modality of anti-cancer therapies [48].”
BackgroundMethodUpdate of KDBI: Kinetic Data of Bio-molecular Interaction database
Kumar, P., Han, B. C., Shi, Z., Jia, J., Wang, Y., Zhang, Y., Liang, L., Liu, Q. F., Ji, Z., & Chen, Y. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn839 · Cited by 26
Antiseizure medication discovery: Recent and future paradigm shifts
Talevi, A. (2022) · Epilepsia Open · doi:10.1002/epi4.12581 · Cited by 25
Systems Biology: An Evolving Approach in Drug Discovery and Development
Ho, R. L., & Lieu, C. A. (2008) · Drugs in R&D · doi:10.2165/00126839-200809040-00001 · Cited by 25
Precision multidimensional assay for high-throughput microRNA drug discovery
Haefliger, B., Prochazka, L., Angelici, B., & Benenson, Y. (2016) · Nature Communications · doi:10.1038/ncomms10709 · Cited by 25
“Yet, these assays still generate candidate compounds that perform inadequately in vivo with respect to efficacy and toxicity 14 in large part because many unwanted interactions 15 pass undetected in vitro .”
BackgroundIshizawa, J., Sugihara, E., Kuninaka, S., Mogushi, K., Kojima, K., Benton, C. B., Zhao, R., Chachad, D., Hashimoto, N., Jacamo, R. O., et al. (2017) · Blood · doi:10.1182/blood-2016-07-726216 · Cited by 25
Huang, J., Zheng, Y., Wu, W., Xie, T., Yao, H. W., Pang, X., Sun, F.-Z., Ouyang, L., & Wang, J. (2015) · Oncotarget · doi:10.18632/oncotarget.3789 · Cited by 25
“Additionally, current strategy for drug discovery is mainly focusing on the “one gene-one drug-one disease” code, which has caused limitations since the drug’s efficacy is impaired by the robustness of protein-protein interaction (PPI) network in the treated objectives [6].”
BackgroundHandbook of Research on Systems Biology Applications in Medicine
Daskalaki, A. (2009) · IGI Global eBooks · doi:10.4018/978-1-60566-076-9 · Cited by 25
Glotzer, S. C., USDOE Office of Science (SC), (NASA), N. A. A. S. A., USDOD, Kim, S., Cummings, P., Deshmukh, A., Head‐Gordon, M., Karniadakis, G. E., Petzold, L. R., et al. (2013) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · doi:10.2172/1088842 · Cited by 25
Azuaje, F. J., Devaux, Y., & Wagner, D. R. (2010) · Biosystems · doi:10.1016/j.biosystems.2010.01.002 · Cited by 24
Screening drug target combinations in disease-related molecular networks
Luo, M., Jiao, J., & Wang, R. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2730-8 · Cited by 24
Modelling and analysis of an ensemble of eukaryotic translation initiation models
Nayak, S., Siddiqui, J. K., & Varner, J. D. (2011) · IET Systems Biology · doi:10.1049/iet-syb.2009.0065 · Cited by 26
Combined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23
Binding sites in membrane proteins – Diversity, druggability and prospects
Adams, R. A., Worth, C. L., Günther, S., Dunkel, M., Lehmann, R., & Preißner, R. (2011) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2011.06.003 · Cited by 23
“Surprisingly, low drug efficacy an be caused by the intrinsic robustness of the network of which he target is a part of Kitano (2007).”
Backgroundvan der Horst, E., Peironcely, J. E., van Westen, G. J. P., van den Hoven, O. O., Galloway, W. R. J. D., Spring, D. R., Wegner, J. K., van Vlijmen, H., IJzerman, A. P., Overington, J. P., et al. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611796391230 · Cited by 24
“This is based partly on our increasing understanding of single interventions, now making partially also possible to engineer desired combinations of interventions, but even more so this is due to the realization that multiple targets are needed to modulate biological networks in the desired manner due to effects such…”
BackgroundAnalyzing of Molecular Networks for Human Diseases and Drug Discovery
Hao, T., Wang, Q., Zhao, L., Wu, D., Wang, E., & Sun, J. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180813143408 · Cited by 24
“Some other studies showed that the neighbors of disease-related proteins are prone to interact with the proteins involving in the same disease [47].”
BackgroundAnimal Models in Drug Development
Greek, R. (2013) · InTech eBooks · doi:10.5772/53893 · Cited by 23
“[8, 9, 29-35] This can be illustrated by the fact that knocking out a gene in one strain of mouse may produce no noticeable effects.”
BackgroundDiverse array-designed modes of combination therapies in Fangjiomics
Liu, J. H., & Wang, Z. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.125 · Cited by 23
Stability Analysis of Genetic Regulatory Networks with Multiple Time Delays
Wu, F. (2007) · Conference proceedings · doi:10.1109/iembs.2007.4352557 · Cited by 23
“Insights into the nature and function of various networks are of interest to many researchers, as it has proved that many diseases (such as cancer and AIDS) stem from the malfunction of genetic regulatory networks of the corresponding cell lines [1,2].”
BackgroundApplication of GQSAR for Scaffold Hopping and Lead Optimization in Multitarget Inhibitors
Ajmani, S., & Kulkarni, S. A. (2012) · Molecular Informatics · doi:10.1002/minf.201100160 · Cited by 22
Filling Kinetic Gaps: Dynamic Modeling of Metabolism Where Detailed Kinetic Information Is Lacking
Reséndis-Antonio, O. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004967 · Cited by 22
“Robustness in metabolic networks has been attributed to a set of factors, with redundancy representing one of the most recognized [36].”
BackgroundTassini, S., Langron, E., Delang, L., Mirabelli, C., Lanko, K., Crespan, E., Kiššová, M., Tagliavini, G., Fontò, G., Bertoni, S., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01416 · Cited by 22
Zheng, C., Xu, X., Ye, H., Wu, G., Li, X., Huang, S., & Liu, X. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1411 · Cited by 22
Goltsov, A., Faratian, D., Langdon, S. P., Mullen, P., Harrison, D. J., & Bown, J. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.09.030 · Cited by 22
Agnati, L. F., Guidolin, D., Leo, G., Guescini, M., Pizzi, M., Stocchi, V., Spano, P., Ghidoni, R., Ciruela, F., Genedani, S., et al. (2011) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2011.599393 · Cited by 22
“(Received 26 May 2011; revised 00 00 0000; accepted 20 June 2011) Journal of Receptors and Signal Transduction, 2011; 31(5): 315–331 © 2011 Informa Healthcare USA, Inc.”
BackgroundStability of Signaling Pathways during Aging—A Boolean Network Approach
Schwab, J. D., Siegle, L., Werle, S. D., Kühl, M., & Kestler, H. A. (2017) · Biology · doi:10.3390/biology6040046 · Cited by 22
Ethnopharmacology and Ethnomedicine-Inspired Drug Development
Mukherjee, P. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813374-3.00002-8 · Cited by 22
Integrating Systems Biology Sources Illuminates Drug Action
Gottlieb, A., & Altman, R. B. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.51 · Cited by 21
“As noted by several authors, 27,28 drug discovery is quickly moving from the single-gene research paradigm to the systems biology analysis paradigm.”
Ram, S., & Goulian, M. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003706 · Cited by 21
Functional models for large-scale gene regulation networks: realism and fiction
Lagomarsino, M. C., Bassetti, B., Castellani, G., & Remondini, D. (2009) · Molecular BioSystems · doi:10.1039/b816841p · Cited by 21
Rosado, J. O., Henriques, J. A. P., & Bonatto, D. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911796798977 · Cited by 22
“Systems pharmacology allows us to understand how drugs act in different tissues and cell types, as well as the effects of multiple actions within a single cell type that are due to the presence of several interacting pathways [16, 19].”
BackgroundMethodInfluentialBai, F., Huang, Z., Luo, J., Qiu, Y., Huang, S., Huang, C., Liu, T., Zhang, H., & Wang, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1164425 · Cited by 20
Wáng, Y., Yu, L., Zhang, L., Qu, H., & Cheng, Y. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2009.00934.x · Cited by 20
“lular functions and interactions among the pathways, which may limit the performance of single-target-drug paradigm (1).”
BackgroundNayak, S., Salim, S., Luan, D., Zai, M., & Varner, J. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002016 · Cited by 20
“Consistent with the conjecture of Kitano, the anecdotal comparison between predicted fragile mechanisms and literature suggested that cell-cycle control architectures are HOT networks [29].”
BackgroundResultShen, L., Liu, Z., Tu, Y., Xu, L., Sun, X., & Wu, S. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0262-4 · Cited by 19
“Additionally, understanding complex network systems may help to identify potential new targets in gastric cancer which can be cured by a molecular approach [30].”
BackgroundTranscriptional response networks for elucidating mechanisms of action of multitargeted agents
Kibble, M., Khan, S. A., Saarinen, N., Iorio, F., Sáez-Rodríguez, J., Mäkelä, S., & Aittokallio, T. A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.03.001 · Cited by 19
Yamamoto, M. (2022) · Gene · doi:10.1016/j.gene.2022.146555 · Cited by 19
Selective antagonism of anticancer drugs for side-effect removal
Fernández, A., & Sessel, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.001 · Cited by 20
Reichle, A. (2010) · Springer eBooks · doi:10.1007/978-90-481-9531-2_2 · Cited by 18
“How may systems pathologies be conceptually characterized? Robustness, stability, and homeostasis of a tumor system describe how a subsystem is controlled during biomodulatory therapies or evolutionary processes [32].”
BackgroundTrade‐off of dynamic fragility but not of robustness in metabolic pathways in silico
Quinton-Tulloch, M. J., Bruggeman, F. J., Snoep, J. L., & Westerhoff, H. V. (2012) · FEBS Journal · doi:10.1111/febs.12057 · Cited by 18
“The most serious threats to biological systems often come from malfunctioning components rather than the loss of components [9].”
BackgroundNetwork connectivity during mergers and growth: Optimizing the addition of a module
Taylor, D., & Restrepo, J. G. (2011) · Physical Review E · doi:10.1103/physreve.83.066112 · Cited by 17
Bioinformatics in protein kinases regulatory network and drug discovery
Chen, Q., Luo, H., Chengqi Zhang, B., & Chen, Y. P. (2015) · Mathematical Biosciences · doi:10.1016/j.mbs.2015.01.010 · Cited by 18
Liang, Y., & Wang, W. (2011) · CHIMIA International Journal for Chemistry · doi:10.2533/chimia.2011.944 · Cited by 18
Wildenhain, J., Spitzer, M., Dolma, S., Jarvik, N., White, R., Roy, M. M., Griffiths, E., Bellows, D. S., Wright, G. D., & Tyers, M. (2016) · Scientific Data · doi:10.1038/sdata.2016.95 · Cited by 18
Bioinformatics approach to identifying molecular biomarkers and networks in multiple sclerosis
Satoh, J. (2010) · Clinical and Experimental Neuroimmunology · doi:10.1111/j.1759-1961.2010.00013.x · Cited by 17
“10 In the scale-free molecular network, targeted disruption of limited numbers of critical components designated the hub, on which the biologically important molecular connections concentrate, could disturb the whole cellular function by destabilizing the network.”
BackgroundAI-driven automated discovery tools reveal diverse behavioral competencies of biological networks
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2025) · eLife · doi:10.31219/osf.io/s6thq · Cited by 17
Sacco, E., Spinelli, M., & Vanoni, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.728586 · Cited by 17
“At the same time, evidence has accumulated that cancer has to be considered a system-level disease [129,130] characterized by a restricted combination of physiological alterations (cancer hallmarks) which together define the phenotype of most human tumors [50].”
Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation
Marucci, G., Ben, D. D., Lambertucci, C., Navia, A. M., Spinaci, A., Volpini, R., & Buccioni, M. (2021) · Molecules · doi:10.3390/molecules26041188 · Cited by 17
Li, F., Li, P., Xu, W., Peng, Y., Bo, X., & Wang, S. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp634 · Cited by 17
“In addition, this type of analysis could have great potential in identifying and validating drug targets (Antal et al., 2009); many drug candidates failed because of the intrinsic robustness of cellular networks against perturbations (Kitano, 2007).”
BackgroundMethodProtein Interactions: Mapping Interactome Networks to Support Drug Target Discovery and Selection
Rivas, J. D. L., & Prieto, C. A. V. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-965-5_12 · Cited by 17
Brandl, M., Pasquier, E., Li, F., Beck, D., Zhang, S., Zhao, H., Kavallaris, M., & Wong, S. T. C. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.007 · Cited by 17
Nishi, A., Kaifuchi, N., Shimobori, C., Ohbuchi, K., Iizuka, S., Sugiyama, A., Ogura, K., Yamamoto, M., Kuroki, H., Nabeshima, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82707-1 · Cited by 16
Self-citationZou, J., Luo, S., Wei, Y.-Q., & Yang, S. (2010) · Molecular BioSystems · doi:10.1039/c0mb00004c · Cited by 15
A ranking method for the concurrent learning of compounds with various activity profiles
Dörr, A., Rosenbaum, L., & Zell, A. (2015) · Journal of Cheminformatics · doi:10.1186/s13321-014-0050-6 · Cited by 15
“It is also a matter of how robust its underlying system is against perturbations [3].”
Krippendorff, B., Oyarzún, D. A., & Huisinga, W. (2012) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-012-9243-7 · Cited by 15
“Such mathematical models allow identifying and ranking potential targets in cellular networks for achieving specific downstream effects [11, 12].”
BackgroundDakik, P., McAuley, M., Chancharoen, M., Mitrofanova, D., Rodriguez, M. E. L., Junio, J. A. B., Lutchman, V., Cortes, B., Simard, É., & Titorenko, V. I. (2019) · Oncotarget · doi:10.18632/oncotarget.26553 · Cited by 15
Comparisons of Robustness and Sensitivity between Cancer and Normal Cells by Microarray Data
Chu, L., & Chen, B. (2008) · Cancer Informatics · doi:10.4137/cin.s386 · Cited by 15
“Multiple feedback redundancies of p53 form the bow-tie architecture, which is robust at systems level but fragile on essential elements such as p53 and MDM2 (Kitano, 2007).”
BackgroundMethodInfluentialBianconi, F., Baldelli, E., Luovini, V., Petricoin, E. F., Crinò, L., & Valigi, P. (2015) · BMC Systems Biology · doi:10.1186/s12918-015-0216-5 · Cited by 15
“Several authors have introduced the visionary idea of applying robustness in drug development [9, 10, 23, 35], although the application of the general definition is still a key problem in Systems Biology.”
BackgroundInfluentialZhang, Y., Chen, Y., Li, Y., Mao, X., Tao, W., Tang, Y., Lin, Y., Guo, Q., Duan, J., & Lin, N. (2017) · Scientific Reports · doi:10.1038/srep41925 · Cited by 15
“The emerging methodologies of this research field are considered with the purpose of finding multiple nodes which can be influenced by herb combinations for interfering with robust disease phenotypes and fewer adverse effects 17 .”
AI-driven automated discovery tools reveal diverse behavioral competencies of biological networksPreprint
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2025) · eLife · doi:10.7554/elife.92683 · Cited by 15
Network‐based precision medicine and systems pharmacology
Pandey, A. K., Ghiassian, S. D., & Loscalzo, J. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70184 · Cited by 14
“Biological networks for these states share several features with highly dynamic systems, which are characterised by high degrees of robustness and resiliency to perturbation (Kitano, 2007).”
Optimizing Cancer Pharmacotherapeutics Using Mathematical Modeling and a Systems Biology Approach
Clairambault, J. (2011) · Personalized Medicine · doi:10.2217/pme.11.20 · Cited by 14
A Network-Based Integrative Workflow to Unravel Mechanisms Underlying Disease Progression
Khan, F. M., Sadeghi, M., Gupta, S. K., & Wolkenhauer, O. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7456-6_12 · Cited by 14
“Their structural analysis allows the identification of functional modules [1–3], regulatory motifs [4, 5], and hub nodes [5, 27–29] along Table 1 Important databases for retrieving interactions for various biochemical interactions”
BackgroundInfluentialYe, Q., Xu, R., Li, D., Kang, Y., Deng, Y., Zhu, F., Chen, J., He, S., Hsieh, C., & Hou, T. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101520 · Cited by 14
Sarma, U., & Ghosh, I. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-287 · Cited by 14
“principles and helps in finding suitable drug targets [39,40].”
BackgroundSingh, K. K., Shekhar, S., Yadav, Y., Xess, I., & Dey, S. (2017) · Journal of Peptide Science · doi:10.1002/psc.2973 · Cited by 14
CEMTDD: Chinese Ethnic Minority Traditional Drug Database
Huang, J., & Wang, J. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1011-2 · Cited by 14
“These data were integrated from web-based databases as well as text-mining from academic books and published articles, such as Kazakh drug Blog, Uygur medicine Blog, Chinese Pharmacopoeia, and Uygur medicine branch which were released by ministry of health in China [2, 3].”
MethodInfluentialBiomolecular Self-Defense and Futility of High-Specificity Therapeutic Targeting
Rosenfeld, S. (2011) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s8542 · Cited by 14
“Some advantages of this method are the following: (1) no model for the dynamics is required; (2) the computations required at each iterate are minimal; (3) the required changes in the parameter can be quite small; (4) different periodic orbits can be stabilized for the same system in the same parameter range; (5) cont…”
MethodIntersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Yousef, M., Trinh, H., & Allmer, J. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140519120855 · Cited by 14
“The miRNA and gene regulatory systems are designed to maintain robust function in face of external perturbations [103] and miRNAs strongly contribute to this robustness [104].”
BackgroundZhang, Y., Wang, P., Geng, Z., Bao, L., Gao, S., Sun, J., Liu, X., Yang, X., Zhao, R., Li, S., et al. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156018 · Cited by 13
Ligeti, B., Pénzváltó, Z., Alvarez, R. V., Győrffy, B., & Pongor, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129267 · Cited by 13
“In the past few decades the number of novel marketed drugs has fallen much below the expectations despite the growing resources invested in this area [1–3].”
BackgroundDynamical analysis of cellular networks based on the Green's function matrix
Perumal, T. M., Wu, Y. L., & Gunawan, R. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.07.037 · Cited by 13
Sakai, N., Terami, H., Suzuki, S., Haga, M., Nomoto, K., Tsuchida, N., Morohashi, K.-I., Saito, N., Asada, M., Hashimoto, M., et al. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0027 · Cited by 13
“However, the combination of these ‘weak’ inhibitors would be able to make pharmacological effect that is defined as ‘long-tail’drugs (Kitano 2007).”
BackgroundHuang, H., He, Y., Wan, L., Wei, W., Li, Y., Xie, R., Guo, S., Wang, Y., Jiang, J., Chen, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9353 · Cited by 13
Network motifs modulate druggability of cellular targets
Wu, F., Ma, C., & Tan, C. (2016) · Scientific Reports · doi:10.1038/srep36626 · Cited by 13
Simple Drugs Do Not Cure Complex Diseases: The Need for Multi-Targeted Drugs
Hornberg, J. J. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00001 · Cited by 13
Systems Biology and Cancer Prevention: All Options on the Table
Rosenfeld, S., & Kapetanović, I. M. (2008) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s1114 · Cited by 13
“Kitano had proposed that cancer may be viewed as a breakdown of normal physiological robustness and change to pathological state that develops its own robustness in addition to using the host’s robustness [6, 15].”
BackgroundComputational pharmacological studies on cardiovascular disease by Qishen Yiqi Diwan
Gu, J., Yuan, G., Zhu, Y., & Xu, X. (2009) · Science China Chemistry · doi:10.1007/s11426-009-0274-x · Cited by 12
Evolutionary scalpels for dissecting tumor ecosystems
Rosenbloom, D. I. S., Cámara, P. G., Chu, T., & Rabadán, R. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.11.005 · Cited by 12
Nazarshodeh, E., Marashi, S., & Gharaghani, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261267 · Cited by 12
Network Topologies Decoding Cervical Cancer
Jalan, S., Kanhaiya, K., Rai, A., Bandapalli, O. R., & Yadav, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135183 · Cited by 12
Robustness and topology of the yeast cell cycle Boolean network
Lee, W.-B., & Huang, J. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.02.010 · Cited by 12
“Robustness analysis helps one to identify essential interactions to a robust biological system, and these essential interactions could be potential drug targets [16].”
BackgroundGerber, S., Assmus, H. E., Bakker, B. M., & Klipp, E. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2007.09.027 · Cited by 12
In silico Genetic Network Models for *Pre-clinical Drug PrioritizationPreprint
Xiong, J., Xiong, J., Liu, J., Rayner, S., Tian, Z., Li, Y., & Chen, S. (2010) · Nature Precedings · doi:10.1038/npre.2010.5343 · Cited by 12
Xie, L., Kinnings, S., Xie, L., & Bourne, P. E. (2012) · Wiley eBooks · doi:10.1002/9781118274408.ch7 · Cited by 11
Nonlinear Analysis for a Type-1 Diabetes Model with Focus on T-Cells and Pancreatic β-Cells Behavior
Gamboa, D., Vázquez, C. E., & Campos-Hernández, P. J. (2020) · Mathematical and Computational Applications · doi:10.3390/mca25020023 · Cited by 11
Wada, Y., Nishiyama, M., Uehara, H., Sato, K. C., Hamamoto, Y., Ogihara, H., Nishi, A., Asakawa, T., & Yamamoto, M. (2022) · Gene · doi:10.1016/j.gene.2022.146262 · Cited by 11
Robust multi‐drug therapy design and application to insulin resistance in type 2 diabetes
Luni, C., & Doyle, F. J. (2011) · International Journal of Robust and Nonlinear Control · doi:10.1002/rnc.1756 · Cited by 11
Ding, D., Ding, Y. R., Li, L. N., Cai, Y. J., & Xu, W. (2009) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822009000200036 · Cited by 11
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.